- Chimeric Activin A/BMP7 protein with over 30x higher activity compared to natural BMP7
- DRT-101 beats BMP-7 on activation of pro-chodrocytic gene expression
- Current preclinical data indicate DRT-101 potential as a first-in-class DMOAD
- Additional efficacy and safety studies to complete an IND-enabling package are underway
- Target 2026 IND submission (Korea) and subsequent submissions to other regulatory agencies to follow (EU, US)
- DRT-101 shows 30-fold higher activity compared to the natural ligand BMP-7
